These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 11080454)

  • 1. Structural basis for the binding of an immunodominant peptide from myelin basic protein in different registers by two HLA-DR2 proteins.
    Li Y; Li H; Martin R; Mariuzza RA
    J Mol Biol; 2000 Nov; 304(2):177-88. PubMed ID: 11080454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor.
    Madsen LS; Andersson EC; Jansson L; krogsgaard M; Andersen CB; Engberg J; Strominger JL; Svejgaard A; Hjorth JP; Holmdahl R; Wucherpfennig KW; Fugger L
    Nat Genet; 1999 Nov; 23(3):343-7. PubMed ID: 10610182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA-DR2a is the dominant restriction molecule for the cytotoxic T cell response to myelin basic protein in DR2Dw2 individuals.
    Jaraquemada D; Martin R; Rosen-Bronson S; Flerlage M; McFarland HF; Long EO
    J Immunol; 1990 Nov; 145(9):2880-5. PubMed ID: 1698864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The HLA-DP2 protein binds the immunodominant epitope from myelin basic protein, MBP85-99, with high affinity.
    Hansen BE; Nielsen CH; Madsen HO; Ryder LP; Jakobsen BK; Svejgaard A
    Tissue Antigens; 2011 Mar; 77(3):229-34. PubMed ID: 21299528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones.
    Wucherpfennig KW; Sette A; Southwood S; Oseroff C; Matsui M; Strominger JL; Hafler DA
    J Exp Med; 1994 Jan; 179(1):279-90. PubMed ID: 7505801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The autoimmune TCR-Ob.2F3 can bind to MBP85-99/HLA-DR2 having an unconventional mode as in TCR-Ob.1A12.
    Kato Z; Stern JN; Nakamura HK; Miyashita N; Kuwata K; Kondo N; Strominger JL
    Mol Immunol; 2010; 48(1-3):314-20. PubMed ID: 20810170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ligand motifs of HLA-DRB5*0101 and DRB1*1501 molecules delineated from self-peptides.
    Vogt AB; Kropshofer H; Kalbacher H; Kalbus M; Rammensee HG; Coligan JE; Martin R
    J Immunol; 1994 Aug; 153(4):1665-73. PubMed ID: 7519208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular dynamics at the receptor level of immunodominant myelin basic protein epitope 87-99 implicated in multiple sclerosis and its antagonists altered peptide ligands: triggering of immune response.
    Mantzourani ED; Platts JA; Brancale A; Mavromoustakos TM; Tselios TV
    J Mol Graph Model; 2007 Sep; 26(2):471-81. PubMed ID: 17392002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, engineering, and production of human recombinant t cell receptor ligands derived from human leukocyte antigen DR2.
    Chang JW; Mechling DE; Bächinger HP; Burrows GG
    J Biol Chem; 2001 Jun; 276(26):24170-6. PubMed ID: 11319230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T cell response to myelin basic protein in the context of the multiple sclerosis-associated HLA-DR15 haplotype: peptide binding, immunodominance and effector functions of T cells.
    Vergelli M; Kalbus M; Rojo SC; Hemmer B; Kalbacher H; Tranquill L; Beck H; McFarland HF; De Mars R; Long EO; Martin R
    J Neuroimmunol; 1997 Aug; 77(2):195-203. PubMed ID: 9258250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predominant and stable T cell responses to regions of myelin basic protein can be detected in individual patients with multiple sclerosis.
    Salvetti M; Ristori G; D'Amato M; Buttinelli C; Falcone M; Fieschi C; Wekerle H; Pozzilli C
    Eur J Immunol; 1993 Jun; 23(6):1232-9. PubMed ID: 7684682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients.
    Valli A; Sette A; Kappos L; Oseroff C; Sidney J; Miescher G; Hochberger M; Albert ED; Adorini L
    J Clin Invest; 1993 Feb; 91(2):616-28. PubMed ID: 7679413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myelin basic protein-specific T lymphocyte repertoire in multiple sclerosis. Complexity of the response and dominance of nested epitopes due to recruitment of multiple T cell clones.
    Meinl E; Weber F; Drexler K; Morelle C; Ott M; Saruhan-Direskeneli G; Goebels N; Ertl B; Jechart G; Giegerich G
    J Clin Invest; 1993 Dec; 92(6):2633-43. PubMed ID: 7504690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies against a class II HLA-peptide complex raised by active immunization of mice with antigen mimicking peptides.
    Dam-Tuxen R; Riise E
    Scand J Immunol; 2009 Aug; 70(2):93-100. PubMed ID: 19630914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential activation of human autoreactive T cell clones by altered peptide ligands derived from myelin basic protein peptide (87-99).
    Vergelli M; Hemmer B; Utz U; Vogt A; Kalbus M; Tranquill L; Conlon P; Ling N; Steinman L; McFarland HF; Martin R
    Eur J Immunol; 1996 Nov; 26(11):2624-34. PubMed ID: 8921948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunity to T cell receptor peptides in multiple sclerosis. III. Preferential immunogenicity of complementarity-determining region 2 peptides from disease-associated T cell receptor BV genes.
    Bourdette DN; Chou YK; Whitham RH; Buckner J; Kwon HJ; Nepom GT; Buenafe A; Cooper SA; Allegretta M; Hashim GA; Offner H; Vandenbark AA
    J Immunol; 1998 Jul; 161(2):1034-44. PubMed ID: 9670985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Visualization of myelin basic protein (MBP) T cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (HLA)-DR2-MBP 85-99 complex.
    Krogsgaard M; Wucherpfennig KW; Cannella B; Hansen BE; Svejgaard A; Pyrdol J; Ditzel H; Raine C; Engberg J; Fugger L
    J Exp Med; 2000 Apr; 191(8):1395-412. PubMed ID: 10770805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A functional and structural basis for TCR cross-reactivity in multiple sclerosis.
    Lang HL; Jacobsen H; Ikemizu S; Andersson C; Harlos K; Madsen L; Hjorth P; Sondergaard L; Svejgaard A; Wucherpfennig K; Stuart DI; Bell JI; Jones EY; Fugger L
    Nat Immunol; 2002 Oct; 3(10):940-3. PubMed ID: 12244309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals.
    Martin R; Jaraquemada D; Flerlage M; Richert J; Whitaker J; Long EO; McFarlin DE; McFarland HF
    J Immunol; 1990 Jul; 145(2):540-8. PubMed ID: 1694881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crystal structure of HLA-DR2 (DRA*0101, DRB1*1501) complexed with a peptide from human myelin basic protein.
    Smith KJ; Pyrdol J; Gauthier L; Wiley DC; Wucherpfennig KW
    J Exp Med; 1998 Oct; 188(8):1511-20. PubMed ID: 9782128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.